AbbVie

Total: $180.3 million

Top 2 drugs
Humira (arthritis): $62 million; Humira (psoriasis): $36.7 million
Androgel: $45.6 million
Watch the Humira TV commercial here >>

One might wonder why a company that has the best-selling drug in the world--and one that is slated to remain the best-selling drug for the next 5 years--would feel the need to spend money advertising it. The reason is that until AbbVie ($ABBV) can push some new drugs out of its pipeline, the company will rise, or fall, on sales of the arthritis drug. Humira generated $9.6 billion in global revenues last year. The advertising must be helping because U.S. sales were up 19% to $2.18 billion in the first half of 2013.

AbbVie
Read more on

Suggested Articles

Several of GlaxoSmithKline's vaccines are riding strong momentum and now the drugmaker is selling two assets to focus on those growth products.

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.